|March 21, 2014|
|10:53 EDT||ICPT, GES, STAA, JASO||Options with decreasing implied volatility: STAA ICPT JASO RSX GES|
News For STAA;ICPT;JASO;GES From The Last 14 Days
|November 25, 2015|
|12:14 EDT||GES||On The Fly: Top stock stories at midday|
Stocks began the session in positive territory and have remained there throughout the morning, moving in a narrow range on fairly light volume as expected on a get-away day for many investors ahead of Thanksgiving. The tepid trading comes amid a packed economic calendar, with a number of reports that are usually scheduled for release on other days of the week being accelerated due to the holiday. ECONOMIC EVENTS: In the U.S., there was a very busy slate of economic data as several days of reports were crammed into a single morning. Jobless claims fell to 260,000 in the week ended November 21, versus expectations for 270,000 first-time claims. Personal income rose 0.4% in October, matching expectations, while spending rose 0.1%, versus expectations for spending to rise 0.3%. Durable goods orders were up 3.0% last month, versus expectations of up 1.7%. When transportation items are removed, the core reading was up 0.5%, versus expectations for it to be up 0.3%. The FHFA home price index rose 0.8% in September to a reading of 226.5. Markit's services index improved to 56.5 in the flash reading for November, topping the 55.1 forecast. New home sales rose 10.7% to a 495,000 rate in October. Consumer sentiment rose to 91.3 in the final November print of the University of Michigan survey, up from October's 90.0 reading but down from the preliminary 93.1 November reading. COMPANY NEWS: Shares of HP Inc. (HPQ) and HP Enterprise (HPE) moved in opposite directions following their last combined earnings report. HP Inc., which was downgraded by Needham analyst David Rold to Hold following last night report, fell 13% near midday. Meanwhile, HP Enterprise, which announced an Azure cloud partnership with Microsoft (MSFT) in addition to its results, gained about 3%... Deere (DE), which reported better than expected earnings and issued a 2016 sales outlook that met expectations, gained nearly 4% following its quarterly report. MAJOR MOVERS: Among the notable gainers was Pandora (P), which rallied almost 5% after it said that the Register of Copyrights ruled that it couldn't offer an opinion to counter the current "non-differentiated rate structure of licensors." Also higher was Guess (GES), which gained 8% after it reported quarterly earnings and provided guidance. Among the noteworthy losers were SunEdison (SUNE) and TerraForm Power (TERP), which fell 14% and 15%, respectively, after an analyst from UBS downgraded both companies' stocks, saying they are facing considerable risk after personnel changes at TerraForm. Also lower was PTC Therapeutics (PTCT), which lost 5% after Jefferies analyst Gena Wang downgraded its shares to Underperform, saying yesterday's FDA panel for BioMarin's (BMRN) competing muscular dystrophy drug is a negative for PTC. Following yesterday's FDA meeting, BioMarin slipped fractionally and Sarepta (SRPT), which is also competing in the same therapeutic area, was flat. INDEXES: Near midday, the Dow was up 23.48, or 0.13%, to 17,835.67, the Nasdaq was up 19.14, or 0.38%, to 5,121.94, and the S&P 500 was up 2.27, or 0.11%, to 2,091.41.
|11:47 EDT||GES||Guess surges after Q3 profit beats estimates|
Shares of Guess (GES), which licenses and distributes apparel and accessories, are advancing after the company's third quarter profit surpassed analysts' consensus estimates. WHAT'S NEW: Last night, Guess reported Q3 earnings per share of 15c, beating estimates of 11c, and revenue of $521M, matching the consensus forecast. In constant currency, total net revenue decreased 3.9%. Q3 retail comparable sales including e-commerce decreased 6% in U.S. dollars and 2% in constant currency. Victor Herrero, Chief Executive Officer, commented, "I am pleased to report that third quarter results were better than our expectations. Our European retail business was especially strong with a double digit comp sales increase for the quarter for the first time in five years." GUIDANCE: Looking ahead to Q4, Guess forecast EPS of 53c-62c, versus consensus of 59c. It sees Q4 net revenues to range between a decline of 1.5% and an increase of 1.5% in constant currency, compared to consensus of $662.8M. Currency headwinds are expected to negatively impact consolidated revenue growth by approximately 5.5%, for a net decline between 7.0% and 4.0%. The estimated impact on earnings per share of the currency headwinds is approximately 18c. For FY16, Guess raised the bottom end of its EPS outlook to 93c-$1.02 from 89c-$1.02, compared to consensus of 96c. FY16 revenue is forecast to decline between 1.5% and 0.5% in constant currency, versus consensus of $2.21B. Currency headwinds are expected to negatively impact consolidated revenue growth by approximately 8.0%, for a net decline between 9.5% and 8.5%. The estimated impact on FY16 earnings per share of the currency headwinds is approximately 40c. PRICE ACTION: In late morning trading, Guess rose $1.60, or about 8.2%, to $21.14 on heavy trading volume. Despite today's advance, the shares have lost approximately 7% over the past 12 months. OTHERS TO WATCH: Other companies that distribute and license apparel and accessories include PVH Corp. (PVH), Ralph Lauren (RL), Perry Ellis (PERY) and VF Corp. (VFC).
|09:24 EDT||GES||On The Fly: Pre-market Movers |
UP AFTER EARNINGS: Deere (DE), up 4.7%... TiVo (TIVO), up 4.6%... HP Enterprise (HPE), up 2.9%... Qunar (QUNR), up 2.7%... Guess (GES), up 7%. ALSO HIGHER: Aduro BioTech (ADRO), up 6.1% after confirming that all clinical trials are continuing unaltered as planned... American Capital (ACAS), up 6.9% after announcing strategic review of alternatives and expanding its share buyback program to $1B... Pandora (P), up 5.3% after reporting the opinion of the Register of Copyrights. DOWN AFTER EARNINGS: 21Vianet (VNET), down 2.3%... HP Inc. (HPQ), down 9.1%. ALSO LOWER: TerraForm Power (TERP), down 6.1% after being downgraded to Sell from Neutral at UBS... Sunedison (SUNE), down 6.6% after being downgraded to Sell from Neutral at UBS... BioMarin (BMRN), down 2.9% after FDA panel meeting about its New Drug Application for Kyndrisa.
|November 24, 2015|
|19:26 EDT||GES||On The Fly: After Hours Movers |
UP AFTER EARNINGS: Veeva Systems (VEEV), up 7.1%... Guess (GES), up 4.7%... HP Enterprise (HPE), up 2%. ALSO HIGHER: Aduro BioTech (ADRO), up 2.8% after confirming that all clinical trials are continuing unaltered as planned... Prima BioMed (PBMD), up 1.6% after filing its investor update ahead of its General Meeting. DOWN AFTER EARNINGS: HP Inc. (HPQ), down 7.4% after reporting quarterly results.
|16:19 EDT||GES||Guess now sees FY16 EPS 93c-$1.02, consensus 96c|
Sees FY16 revenue to decline between 1.5% and 0.5% in constant currency. Currency headwinds are expected to negatively impact consolidated revenue growth by approximately 8.0%, for a net decline between 9.5% and 8.5%. The estimated impact on FY16 earnings per share of the currency headwinds is approximately 40c.
|16:18 EDT||GES||Guess sees Q4 EPS 53c-62c, consensus 59c|
Subscribe for More Information
|16:17 EDT||GES||Guess reports Q3 EPS 15c, consensus 11c|
Subscribe for More Information
|15:23 EDT||GES||Notable companies reporting after market close |
Notable companies reporting after the market close, with earnings consensus, include HP Enterprise (HPE), consensus 52c... Hewlett-Packard (HPQ), consensus 45c... Veeva (VEEV), consensus 11c... Guess (GES), consensus 11c... Caleres (CAL), consensus 78c... TiVo (TIVO), consensus 8c.
|14:17 EDT||GES||Guess technical notes ahead of earnings|
The stock has been basing, with a bullish bias, since hitting fresh 52-week lows in March of this year. There is also a very large percentage of the float short at over 27%. If the news is more bullish than traders appear to be positioned for, there could be a much stronger than typical move to the upside. Resistance levels to watch from the current price of $19.82 are at $21.12, $22.39, and $23.45 which is the 52-week high. If the news is bearish, the current recovery could be disrupted. Support levels to watch as potential downside objectives would be at $18.67, $17.83, and $17.29. The 52-week low is at $16.61.
|November 18, 2015|
|07:42 EDT||ICPT||Intercept PBC treatment revenue likely to beat expectations, says Oppenheimer|
Subscribe for More Information
|November 17, 2015|
|08:03 EDT||JASO||Solar module makers outlook positive, says Bernstein|
Subscribe for More Information
|07:04 EDT||JASO||JA Solar reports Q3 EPS 68c, may not compare to consensus 32c|
Subscribe for More Information
|November 16, 2015|
|07:16 EDT||STAA||Stephens to hold a tour|
Booth Tour at AAO 2015 in Las Vegas on November 16.
|November 15, 2015|
|15:08 EDT||ICPT||Intercept reports analysis of Phase 3 obeticholic acid study, other data|
Intercept announced results from three studies in primary biliary cirrhosis, recently renamed primary biliary cholangitis, for presentation at the American Academy for the Study of Liver Diseases annual meeting. The studies evaluate investigational use of obeticholic acid, Intercept's lead farnesoid X receptor agonist. In a presentation titled, "Clinical Epidemiology of Primary Biliary Cirrhosis based on a Large U.S. Laboratory Database: Incidence and Trends in Serum Alkaline Phosphatase," an analysis of a clinical database of more than 575,000 patients who received an anti-mitochondrial antibody test showed that, of those patients, 6,107 were classified as having probable PBC based on a positive AMA test and ALP greater than the upper limit of normal at any time prior to AMA testing or up to one month following AMA testing. The study found that 69% of those likely PBC patients continued to have elevated ALP two years after the first positive AMA test. Meanwhile, a presentation titled "A Trial-Based Model of Liver Transplant and Liver-Related Death in Patients with Primary Biliary Cirrhosis" includes an analysis of data from the Phase 3 POISE trial of OCA in PBC using the UK-PBC predictive model of transplant-free survival based on ALP, bilirubin, alanine transaminase, albumin and platelet count. Risk was assessed at 5, 10 and 15 years based on a 12-month change from baseline in patients treated with OCA plus or minus ursodiol or placebo plus or minus ursodiol at the end of the POISE study. The UK-PBC risk algorithm showed a significantly lower risk of liver transplant or liver-related death in OCA-treated patients compared to placebo. Lastly, a presentation titled "Physician versus Patient Perceptions of Medical Care Quality in Primary Biliary Cirrhosis" showed that patients may not be properly informed about their ALP scores and the nature of PBC symptoms.
|14:38 EDT||ICPT||Intercept reports analyses of OCA in fatty liver patients|
Intercept Pharmaceuticals announced new results from the non-invasive evaluation of liver fibrosis in patients from the FLINT trial of obeticholic acid, or OCA, for the treatment of nonalcoholic steatohepatitis, or NASH. In the trial, treatment with once daily 25 mg OCA was shown to reverse fibrosis in a "significant proportion" of biopsy-proven NASH patients, as observed by repeat liver biopsy at the end of the double-blind treatment phase at week 72, according to the company. Post-hoc analysis evaluated the early predictive value of three known non-invasive fibrosis tests -- FIB-4, APRI and NFS -- in identifying patients who experienced improvement in fibrosis. Each was assessed at baseline and over the course of treatment and then correlated with histologic changes observed in the OCA and placebo patients. The analysis demonstrated that OCA treatment of NASH patients led to a statistically significant decrease in FIB-4 from baseline as compared to placebo. Further, a decline in FIB-4 of 10% after 24 weeks of treatment predicted improvement in fibrosis by at least one stage as assessed by biopsy at 72 weeks, according to Intercept. Similarly, OCA-treated patients experienced a significant decrease in APRI as compared to placebo, and a 34% reduction in APRI at 24 weeks predicted improvement in fibrosis by at least one stage at 72 weeks. On average, OCA treatment reduced the FIB-4 score to less than 1.3 and the APRI score to less than 0.5, the respective cut-off values associated with advanced fibrosis, while placebo patients remained above these cut-offs. While NFS declined in the OCA-treated patients and increased in the placebo patients, it did not appear to be sensitive to changes in fibrosis, the company said.